Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis

Fig 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram

Fig 2. Network of treatment comparisons for saphenous vein graft failure (primary efficacy outcome) and major bleeding (primary safety outcome). Each node represents different active interventions or placebo. Size of nodes is proportional to number of studies comparing respective nodes. Increasing thickness of lines between nodes is proportional to number of randomly assigned patients contributing to direct comparisons. Vit K A=vitamin K antagonist

Fig 3. Network meta-analysis and certainty of evidence for saphenous vein graft failure (primary efficacy outcome) and major bleeding (primary safety outcome). Results are odds ratios (95% confidence intervals) from the network meta-analysis between the column defining intervention and row defining intervention. Significant results are in bold. Certainty of evidence is also given: green=moderate certainty evidence, yellow=low certainty evidence, red=very low certainty evidence

Fig 4. Network of treatment comparisons for secondary outcomes all cause mortality and myocardial infarction. Each node represents different active interventions or placebo. Size of nodes is proportional to number of studies comparing respective nodes. Increasing thickness of lines between nodes is proportional to number of randomly assigned patients contributing to direct comparisons. Vit K A=vitamin K antagonist

Fig 5. Network meta-analysis and certainty of evidence for secondary outcomes all cause mortality and myocardial infarction. Results are odds ratios (95% confidence intervals) from the network meta-analysis between the column defining intervention and the row defining intervention. Certainty of evidence is also given: green=moderate certainty evidence, yellow=low certainty evidence, red=very low certainty evidence